A Study to Increase Understanding About Pancreatic Cancer Genetics and Response to Drug Therapy


About this study

The purpose of this study is to learn more about pancreatic cancer genetics in association with response to drug therapy. Pancreatic cancer has identifiable genetic (DNA) changes, yet for many it is not known whether these affect response to cancer drugs.



Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Has a diagnosis of Pancreatic cancer, with at least 1 site accessible for biopsy
  • Willing to undergo research biopsy for creation of xenograft
  • Ability to provide written consent
  • Genetic variant on screening test that affects DNA repair, or a personal/family history of cancer strongly suggestive of such a variant

Exclusion Criteria

  • Must have no contraindications to biopsy (e.g. bleeding disorders, or a need for anticoagulation that cannot be safely held or bridged)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Robert McWilliams, M.D.

Open for enrollment

Contact information:

Robert McWilliams M.D.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer